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Abstract Recent observations connected DNA cytosine
deaminase APOBEC3B to the genetic evolution of
breast cancer. We addressed whether APOBEC3B is associat-
ed with breast cancer clinical outcomes. APOBEC3B messen-
ger RNA (mRNA) levels were related in 1,491 primary breast
cancers to disease-free (DFS), metastasis-free (MFS),
and overall survival (OS). For independent validation,
APOBEC3B mRNA expression was associated with patient
outcome data in five additional cohorts (over 3,500 breast
cancer cases). In univariate Cox regression analysis, increasing
APOBEC3B expression as a continuous variable was associat-
ed with worse DFS, MFS, and OS (hazard ratio [HR]=1.20,
1.21, and 1.24, respectively; all P<.001). Also, in untreated
ER-positive (ER+), but not in ER−, lymph-node-negative pa-
tients, high APOBEC3B levels were associated with a poor
DFS (continuous variable: HR=1.29, P=.001; dichotomized
at the median level, HR=1.66, P=.0002). This implies that
APOBEC3B is a marker of pure prognosis in ER+disease.
These findings were confirmed in the analyses of five inde-
pendent patient sets. Inthese analyses,APOBEC3B expression
dichotomized at the median level was associated with adverse
outcomes (METABRIC discovery and validation, 788 and 706
ER+cases, disease-specific survival (DSS), HR=1.77 and
HR=1.77, respectively, both P<.001; Affymetrix dataset,
754 ER+cases, DFS, HR=1.57, P=2.46E-04; NKI295, 181
ER+cases, DFS, HR=1.72, P=.054; and BIG 1-98, 1,219
ER+cases, breast-cancer-free interval (BCFI), HR=1.42,
P=0.0079). APOBEC3B is a marker of pure prognosis and
pooroutcomesforER+breastcancer,whichstronglysuggests
that genetic aberrations induced by APOBEC3B contribute to
breast cancer progression.
Introduction
Clinical heterogeneity is a confounding hallmark of breast
cancer. This variation in disease manifestation, also true for
many other cancers, is mirrored in the cancer genome with
hundreds to thousands of somatic mutations in each tumor.
The mutations involvedare mostlybasesubstitutions,but also
include small insertions and deletions, larger-scale events
such as translocations, and catastrophic events such as
chromothripsis and kataegis [34, 4]. Several recent studies
identified the APOBEC deaminase family as a major enzy-
matic source of somatic driver and passenger mutations in
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cytosine-biased mutation pattern dominated by C-to-T transi-
tion mutations [12, 33]. Second, next-generation full genome
sequencing studies revealed strand-coordinated cytosine mu-
tation clusters (called kataegis), consisting predominantly of
C-to-T transitions and C-to-G transversions within 5′-TC di-
nucleotide motifs [20]. Third, the antiviral DNA cytosine
deaminaseapolipoproteinBmessengerRNA(mRNA)editing
enzyme catalytic polypeptide-like 3B (APOBEC3B) was
shown to be overexpressed in cell lines and primary breast
tumors and responsible for elevated levels of genomic uracil
and mutations in cell lines. This correlated with increased
mutational loads in primary tumors [2]. Fourth, APOBEC3B
overexpression caused increased mutational loads, cell
cycle deviations, induction of DNA damage markers,
and ultimately cell death [2, 36, 30]. Finally, recent sequenc-
ing meta-analyses data have underscored the importance of
APOBEC3B in causing both the dispersed and clustered
mutationsinbreastcancerandalsoimplicateditasadominant
mutagen in several additional cancers [3, 28, 1].
APOBEC3B is a member of a larger family of polynucle-
otide cytosine deaminases with diverse physiological func-
tions in innate and adaptive immunity, lipid metabolism, and
heart development [24, 7]. The APOBEC3 subfamily consists
of seven members, APOBEC3A, APOBEC3B, APOBEC3C,
APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H
[6, 16]. APOBEC family members are generally thought of
as innate immune effectors with demonstrated single-stranded
DNA cytosine to uracil (C-to-U) editing activity and the
capacity to restrict the replication of a diverse array of trans-
posons and viruses [11, 35]. APOBEC2 has not yet been
demonstrated to elicit biochemical activity, but the mouse
knockout suggests function in cardiovascular muscle devel-
opment [38, 10, 29]. The family namesake, APOBEC1, is
capable of editing both DNA and RNA cytosines, with a
general role in innate immunity and a specialized role in
APOB mRNA editing [24]. Finally, a last member of the
APOBEC protein family, AID (activation-induced deami-
nase), is a DNA cytosine deaminase that targets rearranged
immunoglobulin gene variables and switches region se-
quences to mediate the distinct processes of somatic
hypermutation and class switch recombination, which are
central to antibody affinity maturation and effector functions,
respectively [9, 27].
As a potential continuous source of genetic aberrations in
breast cancer, we hypothesized that APOBEC3B overexpres-
sion may accelerate cancer progression and lead to poor
clinical outcomes. To test this hypothesis, we quantified
APOBEC3B mRNA levels using reverse-transcriptase-
quantitative PCR (RT-qPCR) in a large series of primary
breast tumors and asked whether expression levels correlate
with disease outcome. To probe the potential link between
APOBEC3B mRNA levels and pure disease prognosis, i.e., to
study the relation with the natural course of the disease,
primary tumors of lymph-node-negative (LNN) breast cancer
patients who did not receive systemic adjuvant therapy were
evaluated separately. To provide independent validation, we
analyzed five additional cohorts representing three distinct
platforms (Illumina, Affymetrix, Agilent) for APOBEC3B
mRNA expression measured by gene-specific probes and
their association with patient outcome data. The combined
results indicate that high levels of APOBEC3B mRNA ex-
pression are a significant prognostic biomarker of poor breast
cancer outcomes, exclusively in cases with ER-positive
primary disease.
Patients and Methods
RT-qPCR Cohort (or Rotterdam Cohort)
One thousand four hundred ninety-one tumor specimens ob-
tained at primary surgery between 1978 and 2000 were se-
lectedfromourliquidnitrogentumorbankattheErasmusMC
(Rotterdam, Netherlands). Inclusion criteria were invasive
breast cancer with freshly frozen tissue available irrespective
of nodal status, tumor size, and type of adjuvant systemic
therapy. Major details of this cohort have been described
before [32], and patient and patho-clinical characteristics are
presented in Table 1. Our institution’s Medical Ethical
Committee approved our protocol for studying molecular
markers associated with disease recurrence in anonymized
tumor tissues (MEC 02·953). In this study, we adhere to the
Code of Conduct of the Federation of Medical Scientific
Societies in the Netherlands (http://www.fmwv.nl/)a n d
report in accordance with the REMARK criteria on clinical
reporting [19] (see Supplementary file and Diagram S1).
RNA Extraction, cDNA Synthesis, and Quantification
by RT-qPCR
The detailed procedure for tissue processing, RNA ex-
traction, cDNA synthesis and quantification of APOBEC3B
mRNA transcripts by RT-qPCR has been described [31]
(see supplement for detailed description).
Validation Cohorts
To validate our findings, we used five published datasets
that contained both microarray and clinical follow-up
data. In these data sets, different primary endpoints were
reported, and various systemic adjuvant therapies were ap-
plied [8, 37, 13, 26].
The Illumina HT-12 v4 microarray data sets reported by
Curtisetal.[8],consistingoftwoindependentdatasets,called
METABRIC discovery (n=997) and METABRIC validation
406 HORM CANC (2014) 5:405–413(n=995), were used. The METABRIC clinical data includes
immunohistochemistry (IHC) ER status as well as disease-
specific (DSS) survival data, where all reported deaths are
attributed to breast cancer and deaths from other causes are
censored. Here, we analyzed ER+samples to establish a
METABRIC discovery ER+sub-cohort (n=788, events=
218) and a METABRIC validation ER+sub-cohort (n=706,
events=214). To determine APOBEC3B mRNA expression
values, microarray probe expression values were used as
published [8].
For the NKI295 microarray cohort, Agilent microarray
probe mRNA expression values of APOBEC3B, and patient
disease-free survival (DFS) of 181 ER+cases according to
IHC, were taken from Van de Vijver et al. [37]. Also, here,
microarrayprobe expressionvalueswereusedasa measure of
APOBEC3B mRNA expression value. Patients who had died
withoutevidenceofdiseaseorwhowerelostduringfollow-up
were censored at last follow-up in DFS analysis.
The Kaplan-Meier Plotter online service (http://kmplot.
com) was used to asses APOBEC3B expression as a
prognostic biomarker from Affymetrix microarrays manually
curated and combined from publically available Gene
Expression Omnibus (GEO) cohorts [13]. GEO cohorts over-
lapping with our Rotterdam cohort mentioned above were
excluded.Intotal,theassembledAffymetrixmicroarraycohort
included in the current study contains 754 ER+samples with
DFS as outcome. Microarray probe expression values were
used as downloaded from the kmplot web site.
BIG 1-98was a prospective randomized,phase III,double-
blind trial of 8,010 postmenopausal women with hormone-
receptor-positive early breast cancer that compares 5 years of
adjuvant tamoxifen or letrozole monotherapy or sequential
treatment with 2 years of one of these agents followed by
3 years of the other between 1998 and 2003 [26]. Formalin-
fixed, paraffin-embedded (FFPE) tissue samples (events=
257) were obtained. Due to overall low recurrence rates in
BIG 1-98, a case-cohort sampling was used, where all cases
(recurrences) with available RNA materials were included,
while non-recurrence cases were sampled according to strati-
fication factors. Included RNA samples were profiled using
the Illumina Whole Genome DASL protocol on the Illumina
HT-12 v4 microarray. Samples were cubic spline normalized
with no background correction using BeadStudio software
(Illumina). Twelve hundred nineteen samples were included
in the analysis. The association of the expression data with
time to disease recurrence (breast-cancer-free interval, BCFI)
was assessed using a weighted analysis methods (generalized
Horvitz-Thompson methods) to adjust estimates and test sta-
tistics to obtain unbiased analyses [28]. The endpoint BCFI
was defined as the time from randomization to the first breast
cancer event including invasive breast cancer recurrence at
local, regional, or distant sites or a new invasive cancer in the
contralateral breast, and ignored second (non-breast) malig-
nancies, censored at death without a prior cancer event or last
follow-up visit.
Statistical Analyses
Univariate and multivariate Cox regression analysis was used
to assess the association of APOBEC3B mRNA expression
levels and/or established clinical-pathological factors such as
nodal status, age, tumor size, grade, and hormone receptor
expressionwithDFS,metastasis-free survival(MFS),orover-
all survival (OS). The Cox proportional hazards model was
used to calculate the hazard ratios (HRs) and their 95 %
Table 1 Patient characteristics and their relationship with APOBEC3B
mRNA expression





All patients 1,491 (100) 0.22 (0.27)
Age (years) NS
a
≤40 190 (12.7) 0.26 (0.36)
41–55 558 (37.3) 0.21 (0.26)
56–70 492 (33.0) 0.21 (0.29)
≥71 251 (16.8) 0.20 (0.23)
Menopausal status NS
b
Premenopausal 632 (42.4) 0.22 (0.29)
Postmenopausal 859 (57.6) 0.21 (0.26)
Nodal status .009
b
N 0 829 (55.6) 0.20 (0.26)
N1 –3 298 (20.0) 0.22 (0.26)
N >3 364 (22.4) 0.25 (0.28)
Tumor size <.001
b
pT1 512 (34.3) 0.19 (0.24)
pT2+unknown 821 (55.0) 0.24 (0.30)




Good/moderate 232 (15.5) 0.18 (0.22)
Unknown 450 (30.1) 0.21 (0.24)





<. 0 0 1
a
ER negative 324 (21.7) 0.41 (0.60)







PR negative 554 (37.2) 0.35 (0.46)
PR positive 937 (62.8) 0.16 (0.18)
NS not significant
aSpearman rank correlation test
bTwo-sample Wilcoxon rank-sum (Mann-Whitney) test followed by a
test for trend if appropriate
cGood/moderate tumor grade was compared to poor grade
dER and PR cutoff based on mRNA expression as described [32]
HORM CANC (2014) 5:405–413 407confidence intervals (95 % CIs) of covariates in the analyses
of DFS, MFS, or OS. Likelihood ratio test was performed to
test whether APOBEC3B mRNA expression or other covari-
ates were related to the hazard. Survival curves were con-
structedfromDFS,MFS,andOSdatausingtheKaplan-Meier
estimator for survival [14]. Log-rank test was used to test for
significant differences between two survival curves. All P
values are two-sided. For the Rotterdam cohort, the STATA
statistical package v.11 was used; for validation, Kaplan-
Meier survival analysis BioJava was used which implements
the R survival package [23] with the exception for the
BIG 1-98 where a weighted analysis as described above was
performed.
Results
Association of APOBEC3B mRNA Expression Levels
with Patient and Clinical and Pathological Characteristics
APOBEC3B mRNA expression levels were quantified in the
Rotterdam cohort (n=1,491) by RT-qPCR of total RNA
samples extracted from freshly frozen tumor tissues from
patients with primary breast cancer [32]. The primers used
here are new but robust because they showed near-identical
specificity and efficiency in comparison to previously validat-
ed APOBEC3B RT-qPCR primers [25, 3] (Supplementary
Fig. S1). In this cohort, mRNA expression of APOBEC3B
was positively correlated with nodal status (P=.009), tumor
size (P<.001), and grade (P<.001) and negatively with both
ER (P<.001)andPR(P<.001) (Table 1).
Association of APOBEC3B mRNA Expression Levels
with Clinical Outcomes
To determine whether APOBEC3B mRNA expression was
associated with clinical outcome in breast cancer, we related
log-transformed values of APOBEC3B using Cox regression
analysis with DFS, MFS, and OS. This analysis, using data
from all 1,491 patients, showed that higher expression levels
of APOBEC3B mRNA as a continuous variable were associ-
ated with worse DFS, MFS, and OS (HR=1.20, 95 % CI=
1.11–1.29; HR=1.21, 95 % CI=1.11–1.31; and HR=1.24,
95 % CI=1.13–1.36; all P<.001).
Because a percentage of patients from the Rotterdam
cohort received adjuvant treatment, which may confound
data analyses, we restricted subsequent analyses to the
829 patients with LNN disease who did not receive any
(neo)adjuvant systemic therapy. Of note, this sub-cohort
is relatively unbiased because patients with LNN disease
at the time this retrospective cohort was collected
(1978–2000) did not receive any (neo)adjuvant systemic
therapy according to the guidelines in the Netherlands at
that time. Thus, analysis of this sub-cohort allowed us
to determine the association of APOBEC3B expression
with the natural course of disease. The median mRNA
expression level was used as an unbiased means to split the
cohort into APOBEC3B-low and APOBEC3B-high expres-
sion groups. In addition, we stratified the cohort based on
ER status because ER+(n=633) and ER−(n=196) breast
cancers are biologically distinct diseases [22, 39].
In the 633 LNN patients with ER+disease, APOBEC3B
mRNA expression split at the median level of the whole
cohort was significantly associated with poor DFS
(HR=1.55, 95 % CI=1.23–1.96, P<.001, Table 2), MFS
(HR=1.66, 95 % CI=1.26–2.17, P<.001, Supplementary
Table S2), and OS (HR=1.68, 95 % CI=1.25–2.24, P<.001
(SupplementaryTableS3).In196LNNcaseswithER−breast
cancer, no significant association was observed with any of
the endpoints. In multivariate Cox regression analysis, togeth-
er with current prognostic markers such age, tumor size, and
grade, steroid hormone receptors and APOBEC3B mRNA
expression remained significant in ER+breast cancer in the
analysis of DFS (HR=1.32, 95 % CI=1.02–1.69, P=.034,
Table 2), MFS (HR=1.43, 95 % CI=1.07–1.91, P=.015,
Supplementary Table S2), and OS (HR=1.44, 95 %
CI=1.06–1.96, P=.02, Supplementary Table S3).
Kaplan-Meier analysis (Fig. 1) was used to visualize
the difference in DFS, MFS, and OS of LNN patients
with ER+disease as a function of low and high APOBEC3B
mRNA expression levels. Patients whose tumors had high
APOBEC3B mRNAexpressionlevelsclearlyfaredworsethan
those with low expression levels (log-rank P value<.001 for
all three analyses).
Corroborating Data from Independent Cohorts
To confirm the results presented above in independent patient
cohorts, we used public data and a sub-selection of the
recently profiled prospectively collected BIG 1-98 co-
hort (see the “Patients and Methods” section). The val-
idation cohorts included the METABRIC discovery and
validation cohorts [8] ,t h eN K I 2 9 5c o h o r ti nw h i c ht h e
MammaPrint prognostic signature was validated [37],
and other public data profiled on Affymetrix arrays and
available via http://www.kmplot.com [13]. Note that, in
contrast to the retrospectively collected LNN Rotterdam
discovery cohort, part of these patients received (neo)
adjuvant systemic therapy and that various primary endpoints
were used in the analysis.
Before analyzing the expression of APOBEC3B using
available gene datasets, the concordance between measuring
APOBEC3B gene expression by RT-qPCR and the gene ex-
pressiononU133Amicroarrayswasassessed(Supplementary
Fig. S2). For this, we had available from our cohort a
total of 309 cases with both RT-qPCR and Affymetrix gene
408 HORM CANC (2014) 5:405–413expression data from the same specimens. Overall, these
independent quantitative measurements of APOBEC3B ex-
pression levels correlated strongly (Spearman rs=0.87,
P<.001) This reassured us that the Affymetrix probeset accu-
rately quantifies APOBEC3B expression, thereby reassuring
that publically available gene expression data can be used to
help validate our findings.
Retrospective analysis in five additional independent pa-
tient sets including one prospectively collected cohort of
patients that received adjuvant therapy (BIG 1-98) confirmed
the relation of APOBEC3B expression dichotomized at the
median level with adverse outcome in ER+breast cancer
(METABRIC discovery, 788 ER+cases OS, HR=1.77,
95 % CI=1.35–2.32, P<.0001; METABRIC validation, 706
ER+cases OS, HR=1.77, 95 % CI=1.34–2.33, P<.0001;
NKI295, 181 ER+cases, HR=1.72, 95 % CI=0.98–3.02,
P=.054; assembled Affymetrix microarray cohort, 754
ER+cases, DFS, HR=1.57, 95 % CI=1.23–2.01,
P=.0002; and BIG 1-98, 1,219 ER+cases, BCFI, HR=
1.42, 95 % CI=1.16–1.73, P=0008). For the assembled
Affymetrix microarray cohort, we further confirmed that
APOBEC3B expression for ER−cases was not associated
with outcome (122 cases, DFS, HR=0.96, 95 % CI=
0.58–1.61, P=.89). Kaplan-Meier plots for the ER+
cases of all five cohorts using the median APOBEC3B
mRNA expression level as an unbiased cutoff are presented
in Fig. 2.
Discussion
The innate immune DNA cytosine deaminase APOBEC3B
was recently identified as a predominant source of context
dependent cytosine base substitution mutations in breast can-
cer [12, 33, 2, 36, 30]. This exciting finding provided a
rationale for the progressive gain of passenger and potentially
also driver mutations over time. This consideration lets us
hypothesize that levels of APOBEC3B might contribute to
cancer progression as mutations acquired over time would
likely be APOBEC3B level dependent. Our results indeed
show that patients with high APOBEC3B mRNA levels in
their primary tumor more rapidly experience disease relapse.
This observation was made using a retrospective cohort of
patients who did not receive any systemic (neo)adjuvant treat-
ment, which suggests that APOBEC3B is indeed a marker of
pure prognosis and a direct contributor to breast cancer pro-
gression. However, also in patients receiving various types of
adjuvant endocrine and/or chemotherapy, the analysis came
out as significant, suggesting that overall, the APOBEC3B
enzyme contributes to breast cancer progression. The prog-
nosticvalue of APOBEC3Bwas especially prominent inER+
disease, suggesting that particularly in this subclass of breast
cancer levels of APOBEC3B may contribute to cancer pro-
gression. A clear negative link between ER and APOBEC3B
expression suggests that estrogens down-regulate this gene.
However, we found no evidence for such a regulation in
Table 2 Univariate and multi-
variate analysis for disease-free
survival in lymph-node-negative
cases with estrogen-receptor-
positive breast cancer (n=633)
HR hazard ratio, CI confidence
interval
a mRNA analyzed as log-
transformed continuous variable
Univariate analysis Multivariate analysis
HR (95 % CI) P value HR (95 % CI) P value
Age (years) P=0.0026 P=0.22
≤40 1 1
41–55 0.65 (0.46–0.91) 0.74 (0.52–1.06)
56–70 0.55 (0.39–0.77) 0.60 (0.33–1.09)
≥71 0.49 (0.32–0.73) 0.52 (0.27–0.99)
Menopausal status P=0.008 P=0.921
Premenopausal 1 1
Postmenopausal 0.73 (0.58–0.92) 0.98 (0.60–1.59)
Tumor size P=0.02 P=0.045
pT1 1 1
pT2 1.31 (1.03–1.66) 1.18 (0.92–1.51)
pT3 1.88 (1.08–3.26) 2.07 (1.18–3.63)
Tumor grade P=0.005 P=0.015
Poor 1 1
Unknown 0.97 (0.75–1.26) 1.05 (0.81–1.37)
Good/moderate 0.60 (0.43–0.84) 0.66 (0.47–0.92)
PR
a 0.90 (0.85–0.96) P=0.001 0.94(0.88–1.00) P=0.055
median APOBEC3B mRNA
High vs Low 1.55 (1.23–1.96) P=0.0002 1.32(1.02–1.69) P=0.034
HORM CANC (2014) 5:405–413 409multiple breast cancer cell lines (Burns, Leonard, and
H a r r i s ,d a t an o ts h o w n ) .W h yAPOBEC3B expression
would only be prognostic in ER+and not in ER−breast
cancer is unclear, especially because expression is higher in
ER−disease. Possibly, the mutator phenotype induced by
APOBEC3B overexpression is not rate limiting in ER−dis-
ease, a so called C class cancer, which is often high grade,
TP53 mutant, and characterized by many copy number aber-
rations [5]. In line with this is our observation of a HR of 1.57
for APOBEC3B overexpression in luminal A breast cancer
(Supplementary analysis), which is considered an M class
cancer driven by mutations rather than copy number
aberrations [5].
Earlier work analyzed the germline DNA of breast cancer
casesversushealthycontrolsandreportedthatadeletionallele
of APOBEC3B may be related to a higher incidence of devel-
oping breast cancer [15, 40, 18]. At first glance, this observa-
tion seems counterintuitive to the results presented here.
However, incidence and progression are two clearly distinct
issues. Higher incidence may be explained by the likelihood
that APOBEC3B null cells are predicted to be more
susceptible to viral infection and insertional mutagenesis by
endogenous elements, which this protein normally serves to
suppress. Our studies strongly suggest a direct role for
APOBEC3B in cancer mutagenesis beyond tumor onset.
Such a link with progression may also be relevant for
other cancer types in which APOBEC3B is implicated
in generating mutational diversity, such as bladder, lung,
head and neck, and cervical cancer; however, this remains
to be explored [3, 28].
Our work indicates that APOBEC3B and its associated
mutator phenotype associate with poor prognosis. This result
contrasts with the consequences of a different mutator pheno-
type in some colorectal cancers. The hereditary non-polyposis
colorectal carcinoma (HNPCC) subclass of colorectal cancers
typically has a germline mutation in a mismatch repair gene
that results in a strong mutator phenotype (microsatellite in-
stability) and is known to increase the incidence of cancer, but
clinically results in better long-term prognosis. The main
difference may be the overall level of mutation. HNPCC
tumors may be more genetically “brittle” in that, while they
are more likely to form, they are also unable to modulate the
A B 
C 
Fig. 1 Kaplan-Meier survival
analysis for the Rotterdam cohort.
Kaplan-Meier curves for disease-
free survival (a), metastasis-free
survival (b), and overall survival
analysis (c) for all 633 lymph-
node-negative patients with
estrogen-receptor-positivedisease
who did not receive any adjuvant
systemic therapy divided at the
median APOBEC3B mRNA ex-
pression level. Red and blue
graphs represent APOBEC3B
mRNA expression below and
above the median respectively. Y-
axis expresses cumulative surviv-
al rate (Color figure online)
410 HORM CANC (2014) 5:405–413level of mutation once the tumor is established, making them
susceptible to lethal hypermutation assisted by therapeutic
intervention. HNPCC tumors cannot easily restore genetic
stability because it is difficult to revert a chromosomal muta-
tion (often germline). In contrast, APOBEC3B-elevated muta-
genesis in breast cancer is more modest, appearing to occur
gradually after the initial tumor has formed [40]. In our work-
ing model, the mutator phenotype provides cancer with a
measure of sub-lethal genetic plasticity that contributes to
diversifying the tumor cell population. Elevated APOBEC3B
expression appears to be at the transcriptional level, which,
depending on the tumor environment, may be up- or down-
modulated. The heterogeneous population resulting from
moderately elevated APOBEC3B expression may then yield





Fig. 2 Kaplan-Meier survival
analysis of validation cohorts
including only cases with
estrogen-receptor-positive dis-
ease. Kaplan-Meier curves for
DSS in the METABRIC discov-
ery (a) and METABRIC valida-
tion cohort (b), for DFS in the
NKI cohort (c) and for DFS in a
combined cohort including publi-
cally available Affymetrix
datasets (d), and for BCFI in the
prospective collected BIG 1-98
cohort (e). All cohorts were di-
vided using the median
APOBEC3B mRNA expression
level. Red and blue graphs repre-
sent APOBEC3B mRNA expres-
sion below and above the median
respectively.
Y-axis expresses cumulative sur-
vival rate (Color figure online)
HORM CANC (2014) 5:405–413 411Our data suggest that more aggressive treatments of ER+
tumors could be considered particularly in those having high
APOBEC3B.Long-lived APOBEC3B-high tumorcells,even
when still dormant, will have more opportunities to accumu-
late mutations, evolve, escape the dormant state, outgrow,
metastasize, and potentially acquire resistance during addi-
tional rounds of therapy. Stronger postoperative treatments to
eradicate APOBEC3B-high, ER+cells may be effective. In
addition, although still in the early stages of development [17,
21], small-molecule inhibition of APOBEC3B activity as a
secondary adjuvant therapy is an attractive prospect.
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